Tango Therapeutics surged 48% in trading after early study results showed promise for its pancreatic cancer treatment. The biotech company's stock jumped following announcement that a combination therapy with Revolution Medicines demonstrated significant tumor reduction in advanced cancer patients. Market participants responded enthusiastically to the potential new treatment option, driving the biotech sector higher.

The combination therapy shrank tumors in 11 of 12 pancreatic cancer patients, according to data released via Bloomberg Terminal. Tango noted that two patient responses still require confirmation from a second scan, but the initial results suggest the drug combination could be effective against one of the most lethal cancers. These results far exceed typical response rates for advanced pancreatic cancer treatments.

The dramatic stock movement reflects investor enthusiasm for the potential treatment. Pancreatic cancer has limited treatment options, and successful therapies command premium valuations. The data positions Tango as a potential leader in oncology drug development, with the company now preparing for further clinical validation and potential regulatory approval pathways that could significantly expand its market opportunity.